Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Pimjetmi

Pharmaceutical Executive Daily: FDA Approves Pimjetmi

Published 1 week ago
Description
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us